Literature DB >> 22777243

Alzheimer disease: Amyloid-β immunotherapy CAD106 passes first safety test in patients with Alzheimer disease.

Katie Kingwell.   

Abstract

Entities:  

Year:  2012        PMID： 22777243     DOI： 10.1038/nrneurol.2012.128

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  1 in total

1.  Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.

Authors:  Bengt Winblad; Niels Andreasen; Lennart Minthon; Annette Floesser; Georges Imbert; Thomas Dumortier; R Paul Maguire; Kaj Blennow; Joens Lundmark; Matthias Staufenbiel; Jean-Marc Orgogozo; Ana Graf
Journal:  Lancet Neurol       Date:  2012-06-06       Impact factor: 44.182
  1 in total
  1 in total

1.  Alzheimer's disease and immunotherapy.

Authors:  Jennifer Madeo; Marianne Frieri
Journal:  Aging Dis       Date:  2013-03-06       Impact factor: 6.745
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.